Latest Regulatory News

BCI Minerals has transitioned to full-scale operations at its Mardie Salt Project, marking a pivotal moment with strong construction progress, secured financing, and binding offtake agreements. The company remains on track for first salt shipment by late 2026.

Helia Group reports a robust 38% rise in statutory net profit for the first half of 2025, alongside a special dividend declaration, while navigating looming challenges from government policy shifts and lender contract changes.

Resolute Mining reported a strong H1 2025 with revenue up 31% driven by soaring gold prices, even as production dipped due to operational challenges. The company advances key projects and maintains full-year guidance amid strategic acquisitions.

Helia Group Limited reported a strong first half of 2025 with a 37.8% jump in net profit, driven by investment gains and low claims, but faces significant challenges as major contracts with Commonwealth Bank and ING Bank are set to end in 2026.

Resolute Mining Limited reported a robust half-year performance for H1 2025, with net profit more than doubling amid higher gold prices, even as production dipped due to operational challenges. The company also expanded its footprint with a strategic acquisition in Côte d’Ivoire.

Coast Entertainment Holdings Limited reported a robust FY25 with record revenue and EBITDA growth, driven by strong visitor numbers and the successful launch of new attractions. The company’s momentum continues into FY26 amid ongoing macroeconomic challenges.

Coast Entertainment Holdings reports its strongest financial year since 2016, driven by a surge in ticket sales and new attractions, while FY26 begins with robust growth and strategic initiatives.

Inghams Group Limited has announced a fully franked ordinary dividend of AUD 0.08 per share for the six months ending June 28, 2025, signaling steady shareholder returns.

Boom Logistics has reported a robust FY25 performance, with a 38% increase in operating earnings per share, underpinned by strong renewables and transmission projects despite challenges in resources and infrastructure.

Zip Co Limited’s FY25 results reveal a powerful US market expansion driving a 147% rise in cash earnings and a strategic Nasdaq dual listing consideration.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.

Zip Co has delivered a standout FY25 with cash earnings soaring 147%, driven by rapid US market expansion. The company is now considering a Nasdaq dual listing to fuel further growth.